Argo Biopharma, Novartis Expand siRNA Collaboration for Cardiovascular Drugs
Argo Biopharma, a Shanghai‑based siRNA drug developer, announced a new strategic cooperation agreement with Novartis...
Novartis
Arrowhead Partners with Novartis for ARO‑SNCA siRNA Therapy
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today unveiled a worldwide licensing and collaboration agreement with Novartis...
BioArctic & Novartis Announce BrainTransporter‑Enabled Neurodegeneration Collaboration – Up to $772 M Potential Pay‑Out
Swedish biopharma BioArctic AB (publ) (STO: BIOA-B) has entered into an option, collaboration, and license...
Novartis’ Atrasentan Approved in China for IgAN Proteinuria Reduction
Switzerland-based Novartis (NYSE: NVS) has received approval from China’s National Medical Products Administration (NMPA) for...
Novartis’ Ianalumab Shows Positive Results in Phase 3 Trials for ITP and Sjögren’s Disease
Swiss pharmaceutical giant Novartis (NYSE: NVS) announced positive top-line results from the Phase 3 VAYHIT2...
Novartis’ Leqvio Approved by FDA as Standalone Therapy for Hypercholesterolemia
Swiss pharmaceutical giant Novartis (NYSE: NVS) announced on August 12, 2025, that the U.S. Food...
Novartis Begins Shipping Next-Gen Anti-VEGF Drug Beovu for Diabetic Macular Edema
Swiss pharmaceutical giant Novartis (NYSE: NVS) announced on August 11, 2025, the initiation of commercial...
Novartis Evaluates Acquisition of Avidity Biosciences to Strengthen Rare Disease Pipeline
According to reports from several news organizations citing insider sources, that Novartis AG (NYSE: NVS)...
Matchpoint Therapeutics Partners with Novartis to Develop Oral Covalent Inhibitors for Inflammatory Diseases
Matchpoint Therapeutics, a privately held biotechnology company based in Watertown, Massachusetts, announced an exclusive option...
Novartis Reports Double-Digit Growth in Q2 and 1H25, Driven by Key Brands
Swiss pharmaceutical giant Novartis (NYSE: NVS) reported double-digit growth in both revenue and net income...
Sironax Partners with Novartis on Brain Delivery Module Platform for CNS Drugs
China-based biotech innovator Sironax has entered into a strategic agreement with Swiss pharmaceutical giant Novartis...
Pascal Qian Appointed General Manager of BMS China Unit
Pascal Qian this week officially assumed the role of General Manager of Bristol-Myers Squibb’s (BMS;...
Novartis’ Coartem Baby Approved by Swissmedic for Newborns and Young Infants
Swiss pharmaceutical giant Novartis (NYSE: NVS) announced that it has received marketing approval from Swissmedic...
Novartis’ Cosentyx Fails to Meet Primary Endpoint in GCAptAIN Study for Giant Cell Arteritis
Swiss pharmaceutical giant Novartis (NYSE: NVS) announced this week that its Phase III GCAptAIN study...
FDA Removes REMS Requirements for BCMA- and CD19-Targeted CAR-T Therapies
The U.S. Food and Drug Administration (FDA) last week announced the removal of Risk Evaluation...
ProFound Therapeutics and Novartis Forge Four-Year Partnership for Cardiovascular Drug Targets
US-based ProFound Therapeutics announced a four-year partnership with Swiss giant Novartis (NYSE: NVS) to discover...
Novartis Completes Acquisition of Regulus Therapeutics for ADPKD Treatment
Swiss giant Novartis (NYSE: NVS) announced the completion of its acquisition of U.S.-based Regulus Therapeutics....
Novartis’ PSMAddition Trial Yields Positive Results for Pluvicto in mHSPC
Swiss pharmaceutical giant Novartis (NYSE: NVS) announced the interim results from its Phase III PSMAddition...
Huadong Medicine Files for NMPA Approval of Ranibizumab Biosimilar
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its market approval filing for a...
Novartis’ Beovu Approved by NMPA for Diabetic Macular Edema Treatment
Swiss giant Novartis’ (NYSE: NVS) Beovu (brolucizumab) received approval from China’s National Medical Products Administration...